Journal article 544 views
Conservation and cloning of CYP51: a sterol 14α-demethylase from Mycobacterium smegmatis / Colin J Jackson; David C Lamb; Timothy H Marczylo; Josie Parker; Nigel L Manning; Diane Kelly; Steven L Kelly
Biochemical and Biophysical Research Communications, Volume: 301, Issue: 2, Start page: 558
Full text not available from this repository: check for access using links below.
<p><span>Inhibition of sterol-14α-demethylase, a cytochrome P450 (CYP51, Erg11p), is the mode of action of azole antifungal drugs, and with high frequencies of fungal infections new agents are required. New drugs that target fungal CYP51 should not inhibit human CYP51, although...
|Published in:||Biochemical and Biophysical Research Communications|
Check full text
No Tags, Be the first to tag this record!
<p><span>Inhibition of sterol-14α-demethylase, a cytochrome P450 (CYP51, Erg11p), is the mode of action of azole antifungal drugs, and with high frequencies of fungal infections new agents are required. New drugs that target fungal CYP51 should not inhibit human CYP51, although selective inhibitors of the human target are also of interest as anticholesterol agents. A strain of </span><em>Saccharomyces cerevisiae</em><span> that was humanized with respect to the amino acids encoded at the </span><em>CYP51</em><span> (</span><em>ERG11</em><span>) yeast locus (BY4741:huCYP51) was produced. The strain was validated with respect to gene expression, protein localization, growth characteristics, and sterol content. The MIC was determined and compared to that for the wild-type parental strain (BY4741), using clotrimazole, econazole, fluconazole, itraconazole, ketoconazole, miconazole, and voriconazole. The humanized strain showed up to >1,000-fold-reduced susceptibility to the orally active azole drugs, while the topical agents showed no difference. Data from growth kinetic measurements substantiated this finding but also revealed reduced effectiveness against the humanized strain for the topical drugs. Cellular sterol profiles reflected the decreased susceptibility of BY4741:huCYP51 and showed a smaller depletion of ergosterol and accumulation of 14α-methyl-ergosta-8, 24(28)-dien-3β-6α-diol than the parental strain under the same treatment conditions. This strain provides a useful tool for initial specificity testing for new drugs targeting CYP51 and clearly differentiates azole antifungals in a side-by-side comparison.</span></p>
Swansea University Medical School